Fri, Jul 25, 2014, 11:10 AM EDT - U.S. Markets close in 4 hrs 50 mins

Recent

% | $
Click the to save as a favorite.

Geron Corporation (GERN) Message Board

protectdeeznutz 3308 posts  |  Last Activity: Jul 23, 2014 7:34 PM Member since: Feb 20, 2014
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • protectdeeznutz protectdeeznutz Jul 23, 2014 7:34 PM Flag

    and guess what he is about to do with that money - exactly, reload ahead of merck buyout confirmation any day now. see u at 56 pps shortie.

  • protectdeeznutz protectdeeznutz Jul 23, 2014 3:56 PM Flag

    i'm about to buy 500k of ARIAD but holding now until someone confirms

  • a nice surprise is waiting for you

  • protectdeeznutz by protectdeeznutz Jul 23, 2014 3:36 PM Flag

    should go through right now just like yesterday morning to instantly wipe out the shorts and take their monies...now that would be hilarious. merck buyout any day now, see u at 56 pps

  • Diabetes is a significantly larger market than Breast.cancer..but like i said, i really do like breastes's mmmm no matter what, and fully support the cause, believe me..i'll wear pink any day

  • They wake up in the middle of the night yelling, "MERCK!!!!!" And then their partners wake them up and comforts them whispering in their ear, "it's ok, it's ok, everything will be just fine at 56 pps on buyout" before turning over to go back to sleep.

    Sentiment: Strong Buy

  • Waking up to Merck buyout confirmation any morning frightens them - 56/buyout, 75/bidding war...per share. smart shorts are covering since they are no longer making money here, and are quietly exiting their positions and now going long MNKD on the heels of Merck buyout news. Simply speaking, the seams are coming apart for shorts.

    More insider buying confirmed, look it up. "Dr. Juergen purchased more than $1.2 million during Thursday, July 17 2014 which casted the VP's confidence regarding unfolding events going forward."

    BTW - go ahead and search on - merck mannkind (shorts hope u don't)

    Sentiment: Strong Buy

  • A lot of positive developments laying ground for Merck buyout...
    1. Danbury recruitment continues, Merck armed with global sales force already on the ground ready to deliver Afrezza
    2. Insiders buying very large blocks - confirmed the other day
    3. 65-68 Million short covering driving PPS even higher, more evidence short interest is declining
    4. 3.5B rev is U.S. market only and based on a conservative model, it does not include revenue from the ASIAPAC, Europe, India, Africa markets (huge)..and does not include valuation for Technosphere, approved Pediatric market (huge), and other expected applications (pain management, medicinal marijuana etc.).
    5. True Value/Fair Value should be 25-35 PPS based on the above, and then...
    6. Add Big Pharma/Merck buyout premium on top of 25-35 PPS equals 56 pps on buyout confirmed any day now, 75 pps on bidding war

    Pay close attention to "A Featured Presentation On Mannkind Corporation's Revolutionary Diabetes Treatment" and pay close attention to Scenario 4 under Slide 14 and also read Slide 15

    Sentiment: Strong Buy

  • "Mr. Steven F. Goldstone is Independent Director of Greenhill & Co., Inc. He currently manages Silver Spring Group, a private investment firm. From 1995 until his retirement in 2000, Mr. Goldstone was chairman and chief executive officer of RJR Nabisco, Inc. (which was subsequently named Nabisco Group Holdings following the reorganization of RJR Nabisco, Inc.). Prior to joining RJR Nabisco, Inc., Mr. Goldstone was a partner at Davis Polk & Wardwell, a law firm in New York City. He is also the non-executive Chairman of ConAgra Foods, Inc. Mr. Goldstone served as a member of the board of directors of Trane, Inc. (f/k/a American Standard Companies, Inc.) from 2002 until 2008 and as a member of the board of directors of Merck & Co. from 2008 until 2012."

    folks...and do not think for one sec this was not by design and that relationships do not matter in biotech. merck/mnkd buyout confirmation any day now, 56/share on buyout, 75/share on bidding war, shorts in retreat
    type in search box "merck mannkind" - shorts hope u do not see this

    Sentiment: Strong Buy

  • "Merck recently outlined its business strategy for 2014 at the JP Morgan Healthcare Conference. Merck has identified diabetes, oncology, vaccines and acute care as its core commercial therapeutic areas and plans to invest in these fields. The company aims to reduce its investments in non-core areas, which will reduce its annual operating expenses by $2.5 billion by the end of 2015. We remind investors that Merck achieved $3.5 billion of synergies from the Schering Plough merger. Meanwhile, the company aims to recover business in its diabetes portfolio in the U.S in 2014. For example, the company has partnered with Pfizer ( PFE ) to expand its diabetes portfolio with an SGLT2 inhibitor."

    Folks - Merck buyout news keeping shorts up at night, 56/share on buyout, 75/share on bidding war. Type in "Merck MannKind" shorts hope u do not see what results show up. Additionally, Insiders Buying Confirmed (go ahead, look it up) - "Dr. Juergen purchased more than $1.2 million during Thursday, July 17 2014 which casted the VP's confidence regarding unfolding events going forward. Shorts know exactly what this means to their game."

    Sentiment: Strong Buy

  • next time you are doing a search, type (merck mannkind) and see what comes up - shorts hope u do not c all the merck buyout chatter, articles, and analyses out there...
    shorts saw the same spike in level 2 and volume as we longs saw on the charts and it scares them ahead of merck news. they are quietly exiting and the smart shorts are now converting to longs and fully supporting mnkd after losing money for years/months. simply speaking, shorts are exhausted and they just are not making money here. let's all thank them for their participation as they exit. LONGS - be nice, no name calling, and hold the door open for them and shake their hands as they leave....then when they get outside, we r.i.i.i.p. their f.a.c.e. off.! sorry, my blood sugar is low right now...
    next time you are doing a search, type (merck mannkind) and see what comes up - shorts hope u do not c all the merck buyout chatter, articles, and analyses out there

    Sentiment: Strong Buy

  • July 21 2014
    Merck, an American company, is the 6th-largest global Big Pharma company, with revenues in 2013 of $44 billion. (This is about two-thirds as much profit as was earned by the number one Big Pharma company, Johnson & Johnson.) MRK's profits are under pressure due to patent expirations of several of its top-selling drugs, including Singulair, Propecia, Clarinex, and Cozaar.

    To beef up its diabetes product line, Merck is also hoping to get FDA approval for ertugliflozin, an SGLT-2 inhibitor, developed in partnership with Pfizer (NYSE:PFE). But the partners have run into trouble getting this drug approved in USA. That gives the edge to the two already approved drugs of that class, Johnson & Johnson's (NYSE:JNJ) Invokana and AstraZeneca's Farxiga. The health concerns delaying ertugliflozin's approval make it unlikely to be a significant player in that space, should it finally become approved.

    Merck has no insulins on the market right now and only one insulin product under development, a long-acting insulin which is a formulation of insulin glargine, which is better known as Lantus, and which is also Sanofi's (NYSE:SNY) current blockbuster. Sanofi's patent on Lantus expires in 2015.

    A long-acting form of Lantus, should it be successful, would be a product that would be marketed along with, rather than in competition with, the fast-acting insulin, Afrezza. Fast-acting insulins only cover the blood sugar spikes that caused by the carbohydrates digested during meals. Afrezza does not significantly affect the fasting insulin levels that are lowered by long-acting insulins.

    So Merck looks like it could be a decent partner for MNKD. It has the sales force needed to reach endocrinologists and PCPs treating patients with diabetes. It does not have any current or pipeline products that compete directly with Afrezza. It can market Afrezza's ability to replace injections without harming any existing product.

    Sentiment: Strong Buy

  • Sorry, could not attach the link but just Google - No More Needles? What You Need to Know about Inhaled Insulin -

    Sentiment: Strong Buy

  • protectdeeznutz protectdeeznutz Jul 23, 2014 1:20 PM Flag

    they are closely watching what happen to the shorts on PUMA and wondering not if, but when it will happen to them on MNKD. Every day, it is consuming their most.intimate thoughts.

  • protectdeeznutz protectdeeznutz Jul 23, 2014 1:12 PM Flag

    mark it

  • waiting to get cleaned out on Merck buyout news...u better cover shortie, a lot of positive developments...
    1. Danbury recruitment continues, Merck armed with global sales force already on the ground ready to deliver Afrezza
    2. Insiders buying very large blocks - confirmed the other day
    3. 65-68 Million short covering driving PPS even higher, more evidence short interest is declining
    4. 3.5B rev is U.S. market only and based on a conservative model, it does not include revenue from the ASIAPAC, Europe, India, Africa markets (huge)..and does not include valuation for Technosphere, approved Pediatric market (huge), and other expected applications (pain management, medicinal marijuana etc.).
    5. True Value/Fair Value should be 25-35 PPS based on the above, and then...
    6. Add Big Pharma/Merck buyout premium on top of 25-35 PPS equals 56 pps on buyout confirmed any day now, 75 pps on bidding war

    Pay close attention to "A Featured Presentation On Mannkind Corporation's Revolutionary Diabetes Treatment" and pay close attention to Scenario 4 under Slide 14 and also read Slide 15

    Sentiment: Strong Buy

  • Better cover shortie, a lot of positive developments...
    1. Danbury recruitment continues, Merck armed with global sales force already on the ground ready to deliver Afrezza
    2. Insiders buying very large blocks - confirmed the other day
    3. 65-68 Million short covering driving PPS even higher, more evidence short interest is declining
    4. 3.5B rev is U.S. market only and based on a conservative model, it does not include revenue from the ASIAPAC, Europe, India, Africa markets (huge)..and does not include valuation for Technosphere, approved Pediatric market (huge), and other expected applications (pain management, medicinal marijuana etc.).
    5. True Value/Fair Value should be 25-35 PPS based on the above, and then...
    6. Add Big Pharma/Merck buyout premium on top of 25-35 PPS equals 56 pps on buyout confirmed any day now, 75 pps on bidding war

    Pay close attention to "A Featured Presentation On Mannkind Corporation's Revolutionary Diabetes Treatment" and pay close attention to Scenario 4 under Slide 14 and also read Slide 15

    Sentiment: Strong Buy

GERN
2.42-0.11(-4.35%)11:10 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.